235 related articles for article (PubMed ID: 17539969)
1. Histopathological bone marrow changes after reduced-intensity hematopoietic stem cell transplantation for follicular lymphoma involving bone marrow.
Maeda T; Shiozawa E; Saito B; Usui T; Nakashima H; Hattori N; Adachi D; Yanagisawa K; Kawakami K; Nakamaki T; Tomoyasu S; Yamochi-Onizuka T; Takimoto M; Ota H
Pathol Int; 2007 Jun; 57(6):378-82. PubMed ID: 17539969
[TBL] [Abstract][Full Text] [Related]
2. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
[TBL] [Abstract][Full Text] [Related]
3. The implication of follicular lymphoma patients receiving allogeneic stem cell transplantation from donors carrying t(14;18)-positive cells.
McGregor DK; Keever-Taylor CA; Bredeson C; Schur B; Vesole DH; Logan B; Chang CC
Bone Marrow Transplant; 2005 Jun; 35(11):1049-54. PubMed ID: 15821762
[TBL] [Abstract][Full Text] [Related]
4. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
[TBL] [Abstract][Full Text] [Related]
6. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
[TBL] [Abstract][Full Text] [Related]
7. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
[TBL] [Abstract][Full Text] [Related]
9. Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy.
Pulsoni A; Starza ID; Frattarelli N; Ghia E; Carlotti E; Cavalieri E; Matturro A; Tempera S; Rambaldi A; Foà R
Br J Haematol; 2007 May; 137(3):216-20. PubMed ID: 17408460
[TBL] [Abstract][Full Text] [Related]
10. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL).
Martín-Henao GA; Picón M; Limón A; Carmona M; Amill B; Azqueta C; López R; González-Barca E; Grañena A; Brunet S; García J
Bone Marrow Transplant; 1999 Mar; 23(6):579-87. PubMed ID: 10217189
[TBL] [Abstract][Full Text] [Related]
11. Histopathology of bone marrow reconstitution after umbilical cord blood transplantation for hematological diseases.
Maeda T; Shiozawa E; Mayumi H; Usui T; Nakashima H; Hattori N; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Tomoyasu S; Yamochi-Onizuka T; Takimoto M; Ota H
Pathol Int; 2008 Feb; 58(2):126-32. PubMed ID: 18199163
[TBL] [Abstract][Full Text] [Related]
12. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
Oliansky DM; Gordon LI; King J; Laport G; Leonard JP; McLaughlin P; Soiffer RJ; van Besien KW; Werner M; Jones RB; McCarthy PL; Hahn T
Biol Blood Marrow Transplant; 2010 Apr; 16(4):443-68. PubMed ID: 20114084
[TBL] [Abstract][Full Text] [Related]
13. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
14. Terminal deoxynucleotidyl transferase-positive cells in trephine biopsies following bone marrow or peripheral stem cell transplantation reflect vigorous B-cell generation.
Wolf E; Harms H; Winkler J; Reulbach U; Kirchner T; Niedobitek G; Baumann I
Histopathology; 2005 Apr; 46(4):442-50. PubMed ID: 15810956
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
18. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation.
Sugita J; Tanaka J; Hashimoto A; Shiratori S; Yasumoto A; Wakasa K; Kikuchi M; Shigematsu A; Miura Y; Tsutsumi Y; Kondo T; Asaka M; Imamura M
Ann Hematol; 2008 Dec; 87(12):1003-8. PubMed ID: 18636260
[TBL] [Abstract][Full Text] [Related]
19. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
